RE:Not a "fudster", just not a pumperWow where do I start with this latest lame attempt at bashing?
In this case, it's easy.
10 patients over the last 132 days.
Or to use the most recent data, 7 since April. Disingenuous at best. Always use the latest data when extrapolating.
At this pace, the end of recruitment, not of trial, is August 2026.
A horrible & misleading extrapolation without considering recent events including new CRO, Investigator Meeting,etc.
Dead money until then.
If you listen to tree-boy and you sell (or don't buy) you could miss out on the most lucrative time period to be a EDT shareholder (2023- 2024). The denouement years.
And with app. 1 patient enrolled per site during a period of 4+ month period, the product is not showing promising to take over the sepsis market any time soon, so no revenues for a big while.
Revenues come after approval (12-18 months?) That's how Biotechs with RCTs work. Stock price is due to lack of effective promotion.
Also, where is the cash we were going to be buried in thanks to Dialco? Let's forget about that adventure altogether I guess.
Dialco deal not great in terms of immediate monetization, but at least it stopped a large percentage of the monthly burn. I suspect that HHD needs a few more years to iron out the barriers (legal, consumer acceptance, sufficient volumes to drive profitabiltiy) I have no doubt it'll get there with a slower than expected paradigm shift and superior technology to help break down the barriers to entry. A great back-pocket asset to own for when things do shift (like a free future asset to Spectral shareholders). When the time comes, the asset could still be worth multi-billions. Infomed needs to build a US distribution infrastructure or sell out the NA rights (or perhaps world wide rights) to a major.
MM